PDUFA goal date is November 30 for Repros' enclomiphene citrate

• The FDA has assigned a PDUFA goal date of November 30 for the completion of its review of the New Drug Application (NDA) for Repros Therapeutics' (NASDAQ:RPRX) enclomiphene citrate (formerly Androxal) for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The review will include an advisory committee meeting.
• Previously: Repros up 21% premarket on Androxal NDA filing (April 2)